Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 9:14:1129459.
doi: 10.3389/fimmu.2023.1129459. eCollection 2023.

Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative

Hector Bonilla  1 , Michael J Peluso  2 , Kathleen Rodgers  3 , Judith A Aberg  4 , Thomas F Patterson  5 , Robert Tamburro  6 , Lawrence Baizer  7 , Jason D Goldman  8   9 , Nadine Rouphael  10 , Amelia Deitchman  11 , Jeffrey Fine  12 , Paul Fontelo  13 , Arthur Y Kim  14 , Gwendolyn Shaw  15 , Jeran Stratford  15 , Patricia Ceger  15 , Maged M Costantine  16 , Liza Fisher  17 , Lisa O'Brien  18 , Christine Maughan  18 , John G Quigley  19 , Vilma Gabbay  20 , Sindhu Mohandas  21 , David Williams  22 , Grace A McComsey  23
Affiliations
Review

Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative

Hector Bonilla et al. Front Immunol. .

Abstract

Although most individuals recover from acute SARS-CoV-2 infection, a significant number continue to suffer from Post-Acute Sequelae of SARS-CoV-2 (PASC), including the unexplained symptoms that are frequently referred to as long COVID, which could last for weeks, months, or even years after the acute phase of illness. The National Institutes of Health is currently funding large multi-center research programs as part of its Researching COVID to Enhance Recover (RECOVER) initiative to understand why some individuals do not recover fully from COVID-19. Several ongoing pathobiology studies have provided clues to potential mechanisms contributing to this condition. These include persistence of SARS-CoV-2 antigen and/or genetic material, immune dysregulation, reactivation of other latent viral infections, microvascular dysfunction, and gut dysbiosis, among others. Although our understanding of the causes of long COVID remains incomplete, these early pathophysiologic studies suggest biological pathways that could be targeted in therapeutic trials that aim to ameliorate symptoms. Repurposed medicines and novel therapeutics deserve formal testing in clinical trial settings prior to adoption. While we endorse clinical trials, especially those that prioritize inclusion of the diverse populations most affected by COVID-19 and long COVID, we discourage off-label experimentation in uncontrolled and/or unsupervised settings. Here, we review ongoing, planned, and potential future therapeutic interventions for long COVID based on the current understanding of the pathobiological processes underlying this condition. We focus on clinical, pharmacological, and feasibility data, with the goal of informing future interventional research studies.

Keywords: SARS- CoV-2; clinical trials; long COVID; long haulers; post-acute sequela of SARS-CoV-2 (PASC); recover; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Most common symptoms reported in long COVID population.
See this image and copyright information in PMC

Similar articles

  • Viral persistence, reactivation, and mechanisms of long COVID.
    Chen B, Julg B, Mohandas S, Bradfute SB; RECOVER Mechanistic Pathways Task Force. Chen B, et al. Elife. 2023 May 4;12:e86015. doi: 10.7554/eLife.86015. Elife. 2023. PMID: 37140960 Free PMC article. Review.
  • Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design.
    Horwitz LI, Thaweethai T, Brosnahan SB, Cicek MS, Fitzgerald ML, Goldman JD, Hess R, Hodder SL, Jacoby VL, Jordan MR, Krishnan JA, Laiyemo AO, Metz TD, Nichols L, Patzer RE, Sekar A, Singer NG, Stiles LE, Taylor BS, Ahmed S, Algren HA, Anglin K, Aponte-Soto L, Ashktorab H, Bassett IV, Bedi B, Bhadelia N, Bime C, Bind MC, Black LJ, Blomkalns AL, Brim H, Castro M, Chan J, Charney AW, Chen BK, Chen LQ, Chen P, Chestek D, Chibnik LB, Chow DC, Chu HY, Clifton RG, Collins S, Costantine MM, Cribbs SK, Deeks SG, Dickinson JD, Donohue SE, Durstenfeld MS, Emery IF, Erlandson KM, Facelli JC, Farah-Abraham R, Finn AV, Fischer MS, Flaherman VJ, Fleurimont J, Fonseca V, Gallagher EJ, Gander JC, Gennaro ML, Gibson KS, Go M, Goodman SN, Granger JP, Greenway FL, Hafner JW, Han JE, Harkins MS, Hauser KSP, Heath JR, Hernandez CR, Ho O, Hoffman MK, Hoover SE, Horowitz CR, Hsu H, Hsue PY, Hughes BL, Jagannathan P, James JA, John J, Jolley S, Judd SE, Juskowich JJ, Kanjilal DG, Karlson EW, Katz SD, Kelly JD, Kelly SW, Kim AY, Kirwan JP, Knox KS, Kumar A, Lamendola-Essel MF, Lanca M, Lee-Lannotti JK, Lefebvre RC, Levy BD, Lin JY, Logarbo BP Jr, Logue JK, Longo MT, Luciano CA, Lutrick K, Malakooti SK, Ma… See abstract for full author list ➔ Horwitz LI, et al. PLoS One. 2023 Jun 23;18(6):e0286297. doi: 10.1371/journal.pone.0286297. eCollection 2023. PLoS One. 2023. PMID: 37352211 Free PMC article.
  • Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design.
    Metz TD, Clifton RG, Gallagher R, Gross RS, Horwitz LI, Jacoby VL, Martin-Herz SP, Peralta-Carcelen M, Reeder HT, Beamon CJ, Chan J, Chang AA, Costantine MM, Fitzgerald ML, Foulkes AS, Gibson KS, Güthe N, Habli M, Hackney DN, Hoffman MK, Hoffman MC, Hughes BL, Katz SD, Laleau V, Mallett G, Mendez-Figueroa H, Monzon V, Palatnik A, Palomares KTS, Parry S, Pettker CM, Plunkett BA, Poppas A, Reddy UM, Rouse DJ, Saade GR, Sandoval GJ, Schlater SM, Sciurba FC, Simhan HN, Skupski DW, Sowles A, Thaweethai T, Thomas GL, Thorp JM Jr, Tita AT, Weiner SJ, Weigand S, Yee LM, Flaherman VJ; RECOVER Initiative. Metz TD, et al. PLoS One. 2023 Dec 21;18(12):e0285351. doi: 10.1371/journal.pone.0285351. eCollection 2023. PLoS One. 2023. PMID: 38128008 Free PMC article.
  • Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC).
    Sherif ZA, Gomez CR, Connors TJ, Henrich TJ, Reeves WB; RECOVER Mechanistic Pathway Task Force. Sherif ZA, et al. Elife. 2023 Mar 22;12:e86002. doi: 10.7554/eLife.86002. Elife. 2023. PMID: 36947108 Free PMC article. Review.
  • Editorial: Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). Updated Terminology for the Long-Term Effects of COVID-19.
    Parums DV. Parums DV. Med Sci Monit. 2023 Jul 1;29:e941595. doi: 10.12659/MSM.941595. Med Sci Monit. 2023. PMID: 37392031 Free PMC article.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - united states, march-June 2020. MMWR Morb Mortal Wkly Rep (2020) 69(30):993–8. doi: 10.15585/mmwr.mm6930e1 - DOI - PMC - PubMed
    1. Malkova A, Kudryavtsev I, Starshinova A, Kudlay D, Zinchenko Y, Glushkova A, et al. Post COVID-19 syndrome in patients with Asymptomatic/Mild form. Pathogens (2021) 10(11). doi: 10.3390/pathogens10111408 - DOI - PMC - PubMed
    1. CDC . National center for immunization and respiratory diseases (NCIRD) DoVD. long COVID or post-COVID conditions (2022). Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/.
    1. National Institute for Health and Care Excellence (NICE) S, of IGNSaRC, (RCGP) GP . COVID-19 rapid guideline: Managing the long-term effects of COVID-19 (2022). Available at: https://www.nice.org.uk/guidance/ng188. - PubMed
    1. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. Condition WHOCCDWGoP-c-. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis (2022) 22(4):e102–e7. doi: 10.1016/S1473-3099(21)00703-9 - DOI - PMC - PubMed

Publication types